1. Home
  2. ROIV vs MKL Comparison

ROIV vs MKL Comparison

Compare ROIV & MKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Roivant Sciences Ltd.

ROIV

Roivant Sciences Ltd.

N/A

Current Price

$38.91

Market Cap

28.7B

Sector

Health Care

ML Signal

N/A

Logo Markel Group Inc.

MKL

Markel Group Inc.

N/A

Current Price

$1,944.01

Market Cap

23.2B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ROIV
MKL
Founded
2014
1930
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
28.7B
23.2B
IPO Year
2021
1999

Fundamental Metrics

Financial Performance
Metric
ROIV
MKL
Price
$38.91
$1,944.01
Analyst Decision
Strong Buy
Hold
Analyst Count
13
7
Target Price
$50.82
★ $1,980.17
AVG Volume (30 Days)
★ 7.1M
54.0K
Earning Date
11-09-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ 91.90
Revenue
$8,260,000.00
★ $15,513,233,000.00
Revenue This Year
$1,870.25
N/A
Revenue Next Year
$271.46
N/A
P/E Ratio
★ N/A
$21.23
Revenue Growth
N/A
★ N/A
52 Week Low
$19.96
$1,704.17
52 Week High
$42.50
$2,207.59

Technical Indicators

Market Signals
Indicator
ROIV
MKL
Relative Strength Index (RSI) 54.07 57.65
Support Level $33.11 $1,918.84
Resistance Level $42.37 $2,008.51
Average True Range (ATR) 1.55 33.57
MACD -0.07 -4.83
Stochastic Oscillator 49.40 50.35

Price Performance

Historical Comparison
ROIV
MKL

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

About MKL Markel Group Inc.

Markel's primary business is property-casualty insurance. The company focuses primarily on specialty lines, ranging from areas such as executive liability to commercial equine insurance. The company uses capital generated by its insurance operations to buy noninsurance operations in diverse areas, such as bakery equipment manufacturing and residential homebuilding.

Share on Social Networks: